Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0449 in Recurrent Glioblastoma Multiforme
NCT00980343Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vismodegib in glioblastoma multiforme (GBM), sponsored by National Cancer Institute. Started Feb 2010; status: completed.
02
Drugs
vismodegib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00980343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00980343.